Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rasagiline mesylate is a monoamine oxidase B inhibitor used clinically for treating Parkinson's disease. Conventional synthesis relies on optical resolution, which limits efficiency and scalability. To overcome these challenges, we developed an enantioselective synthesis route using asymmetric transfer hydrogenation (ATH) of a cyclic propargyl imine intermediate. Although cyclic imines are difficult to reduce due to their rigid structures, this challenge was overcome using a chiral phosphoric acid catalyst with a Hantzsch ester, affording chiral amines in high yield and enantioselectivity. The method was successfully scaled to the gram level, affording rasagiline mesylate with >96% enantiomeric excess. Furthermore, this approach showed broad substrate compatibility, underscoring its general utility in the asymmetric reduction of cyclic imine derivatives. Our strategy offers a practical and scalable alternative to existing methods for the synthesis of rasagiline and structurally related optically active amines.

Download full-text PDF

Source
http://dx.doi.org/10.1002/asia.70286DOI Listing

Publication Analysis

Top Keywords

synthesis rasagiline
8
chiral phosphoric
8
reduction cyclic
8
cyclic imine
8
rasagiline mesylate
8
enantioselective gram-scale
4
synthesis
4
gram-scale synthesis
4
rasagiline
4
rasagiline chiral
4

Similar Publications

Rasagiline mesylate is a monoamine oxidase B inhibitor used clinically for treating Parkinson's disease. Conventional synthesis relies on optical resolution, which limits efficiency and scalability. To overcome these challenges, we developed an enantioselective synthesis route using asymmetric transfer hydrogenation (ATH) of a cyclic propargyl imine intermediate.

View Article and Find Full Text PDF

Multiple Sclerosis (MS), an autoimmune disorder, is characterized by severe neuroinflammation, leading to demyelination and neuronal damage in the CNS, resulting in significant clinical impairment. MS progression involves complex pathological processes like immune cell invasion and cytokine-mediated recruitment to the CNS. Experimental autoimmune encephalomyelitis (EAE), widely used as a model for MS, despite its translational limitations, has been crucial for identifying effective treatments.

View Article and Find Full Text PDF

This systematic review aimed to evaluate the comparative efficacy, safety and cost-effectiveness of safinamide (50/100 mg) versus rasagiline (1 mg) in managing Parkinson's disease (PD). Randomized clinical trials were identified through systematic searches of PubMed, Embase and Cochrane databases (last searched September 2023). Eligibility criteria included studies assessing Unified Parkinson's Disease Rating Scale (UPDRS) scores, On/Off time and adverse events.

View Article and Find Full Text PDF

Parkinson's disease is a progressive neurodegenerative disorder, with rasagiline mesylate (RM), a potent MAO-B inhibitor, used to manage symptoms. However, oral RM administration often leads to gastrointestinal side effects, reducing patient compliance. This study explores dissolving microneedles (DMNs) and hydrogel-forming microneedles (HMNs) for transdermal RM delivery.

View Article and Find Full Text PDF

Two halogenated quinoline derivatives, namely, -(4-fluorophenyl)-1-(quinoline-2-yl)-methanimine () and -(3-chloro-4-fluorophenyl)-1-(quinoline-2-yl)-methanimine () were synthesized and elucidated by spectroscopic techniques. The molecular structures of and revealed that the azomethine functional group in both compounds is coplanar to the quinoline ring as well as the phenyl ring, as is evident by N2-C8-C7-N1 and C7-N1-C4-C3 torsion angles. In the crystal packing of both compounds, there exists intermolecular CH···N hydrogen bonding.

View Article and Find Full Text PDF